The subject product, Tizanidine Hydrochloride, imported in 2 mg and 4 mg tablets, is a central alpha2-adrenergic agonist indicated for the short-term management of spasticity. It is also indicated for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury.
[1] Please importantly note that only the relevant portion of the related is displayed above. You may refer to the said customs ruling for the entire ruling explanation.
[1]. https://rulings.cbp.gov/ruling/N320574